112 related articles for article (PubMed ID: 28549850)
1. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.
Watz H; Uddin M; Pedersen F; Kirsten A; Goldmann T; Stellmacher F; Groth E; Larsson B; Böttcher G; Malmgren A; Kraan M; Rabe KF
Pulm Pharmacol Ther; 2017 Aug; 45():121-123. PubMed ID: 28549850
[No Abstract] [Full Text] [Related]
2. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
Nicholls DJ; Wiley K; Dainty I; MacIntosh F; Phillips C; Gaw A; Mårdh CK
J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
[TBL] [Abstract][Full Text] [Related]
3. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
[TBL] [Abstract][Full Text] [Related]
4. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
[TBL] [Abstract][Full Text] [Related]
5. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
[TBL] [Abstract][Full Text] [Related]
6. Syntheses of a radiolabelled CXCR2 antagonist AZD5069 and its major human metabolite.
Hickey MJ; Allen PH; Caffrey M; Hansen P; Kingston LP; Wilkinson DJ
J Labelled Comp Radiopharm; 2016 Sep; 59(11):432-8. PubMed ID: 27461061
[TBL] [Abstract][Full Text] [Related]
7. The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates.
Uddin M; Betts C; Robinson I; Malmgren A; Humfrey C
Haematologica; 2017 Feb; 102(2):e65-e68. PubMed ID: 27742769
[No Abstract] [Full Text] [Related]
8. Distinct Spatio-Temporal Dynamics of Tumor-Associated Neutrophils in Small Tumor Lesions.
Sody S; Uddin M; Grüneboom A; Görgens A; Giebel B; Gunzer M; Brandau S
Front Immunol; 2019; 10():1419. PubMed ID: 31293583
[TBL] [Abstract][Full Text] [Related]
9. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils.
Pedersen F; Waschki B; Marwitz S; Goldmann T; Kirsten A; Malmgren A; Rabe KF; Uddin M; Watz H
Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29449427
[No Abstract] [Full Text] [Related]
11. CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.
Braber S; Overbeek SA; Koelink PJ; Henricks PA; Zaman GJ; Garssen J; Kraneveld AD; Folkerts G
Eur J Pharmacol; 2011 Oct; 668(3):443-9. PubMed ID: 21458445
[TBL] [Abstract][Full Text] [Related]
12. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
Gordon JR; Li F; Zhang X; Wang W; Zhao X; Nayyar A
J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
[TBL] [Abstract][Full Text] [Related]
13. CXCR2 antagonist attenuates neutrophil transmigration into brain in a murine model of LPS induced neuroinflammation.
Wu F; Chen X; Zhai L; Wang H; Sun M; Song C; Wang T; Qian Z
Biochem Biophys Res Commun; 2020 Aug; 529(3):839-845. PubMed ID: 32616311
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Tazzyman S; Barry ST; Ashton S; Wood P; Blakey D; Lewis CE; Murdoch C
Int J Cancer; 2011 Aug; 129(4):847-58. PubMed ID: 21328342
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.
O'Byrne PM; Metev H; Puu M; Richter K; Keen C; Uddin M; Larsson B; Cullberg M; Nair P
Lancet Respir Med; 2016 Oct; 4(10):797-806. PubMed ID: 27574788
[TBL] [Abstract][Full Text] [Related]
16. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
17. CXCR2 Inhibition - a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol for a randomised controlled trial.
Joseph JP; Reyes E; Guzman J; O'Doherty J; McConkey H; Arri S; Kakkar R; Beckley N; Douiri A; Barrington SF; Redwood SR; Ferro A
Trials; 2017 Oct; 18(1):473. PubMed ID: 29020983
[TBL] [Abstract][Full Text] [Related]
18. Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression.
Wezel A; Lagraauw HM; van der Velden D; de Jager SC; Quax PH; Kuiper J; Bot I
Atherosclerosis; 2015 Aug; 241(2):289-96. PubMed ID: 26062988
[TBL] [Abstract][Full Text] [Related]
19. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
[TBL] [Abstract][Full Text] [Related]
20. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.
Russo RC; Garcia CC; Teixeira MM; Amaral FA
Expert Rev Clin Immunol; 2014 May; 10(5):593-619. PubMed ID: 24678812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
